摘要
据最新报道,α-甲酰基辅酶A消旋酶(AMACR)作为一个重要的固体肿瘤标志物,是设计抗肿瘤剂的一个有吸引力的靶点,其为一种线粒体和过氧化物酶体酶,在胆固醇代谢产物和支链脂肪酸的氧化过程中起着核心作用。人AMACR的三维结构仍然未知。现有研究已报告,采用基于1x74a模板的建模器和不同造型的模型服务器建立同源模型。采用各种可行的程序如PROCHECK, ERRAT, ProSA等对三维模型的生成进行了验证和评价,为找到AMACR强效抑制剂进行对接研究,在对接研究中,利用化合物的活性对这种酶的其他生物进行了分析。在抑制剂研究中,2-甲基肉豆蔻-辅酶A有效结合此酶,并抑制此酶通过氢键与口袋关键残基的相互作用。此外,进行分子动力学模拟,以检验AMACR /2-甲基肉豆蔻酰基辅酶A配合物的稳定性。结果显示,示出了配体和酶的高亲和力,以及在动态条件下氢键相互作用的稳定性。因此,2-甲基肉豆蔻酰基辅酶A已被认为是一个很有前途的先导化合物,为抗AMACR方面一个新的抑制剂。
关键词: α-甲基酰基辅酶A消旋酶,结合自由能计算,智人,同源建模,分子对接,分子动力学,前列腺癌
图形摘要
Current Cancer Drug Targets
Title:Structural Characterization of Alpha-methylacyl-CoA Racemase: Comparative Structural Modeling, Molecular Docking and Dynamic Simulations Studies
Volume: 15 Issue: 9
Author(s): Sumra Wajid Abbasi and Syed Sikander Azam
Affiliation:
关键词: α-甲基酰基辅酶A消旋酶,结合自由能计算,智人,同源建模,分子对接,分子动力学,前列腺癌
摘要: α-Methylacyl-CoA racemase (AMACR) has recently been reported as a vital solid tumor marker and is an attractive target for designing anti-tumor agents. It is a mitochondrial and peroxisomal enzyme which plays a central role in the oxidation of cholesterol metabolites and branched chain fatty acids. The three dimensional structure of human AMACR is still unknown. In the current study, homology model using Modeller and different modelling servers based on 1X74A as template is reported. The three dimensional model generated was validated and evaluated using various available programs like PROCHECK, ERRAT, ProSA energy plots, etc. In order to find potent inhibitors of AMACR, a docking study using compounds reported to be active against this enzyme of other organisms was conducted. Among the studied inhibitors, 2-methylmyristoyl- CoA effectively binds to and inhibits the enzyme by means of hydrogen bond interactions with the key residues of pocket. Moreover, molecular dynamics simulation was carried out to check the stability of AMACR/2-methylmyristoyl-CoA complex. The results illustrated the ligand’s high binding affinity with enzyme and the stability of hydrogen bond interactions in dynamic condition. Hence, 2-methylmyristoyl-CoA has been suggested to be a promising lead compound for the design of new inhibitors against AMACR.
Export Options
About this article
Cite this article as:
Sumra Wajid Abbasi and Syed Sikander Azam , Structural Characterization of Alpha-methylacyl-CoA Racemase: Comparative Structural Modeling, Molecular Docking and Dynamic Simulations Studies, Current Cancer Drug Targets 2015; 15 (9) . https://dx.doi.org/10.2174/156800961509151110145430
DOI https://dx.doi.org/10.2174/156800961509151110145430 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment
Current Pharmaceutical Design Strategies for Overcoming Inherent and Acquired Resistance to EGFR Inhibitors by Targeting Downstream Effectors in the RAS/PI3K Pathway
Current Cancer Drug Targets Gene Therapy for Prostate Cancer: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Tumor Angiogenesis and VEGFR-2: Mechanism, Pathways and Current Biological Therapeutic Interventions
Current Drug Metabolism Editorial (Thematic Issue: Cancer Biomarkers from Bench to Bedside)
Current Cancer Drug Targets Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Retinoids as Differentiating Agents in Oncology: A Network of Interactions with Intracellular Pathways as the Basis for Rational Therapeutic Combinations
Current Pharmaceutical Design Recent Advances Involving Palladium (II) Complexes for the Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Lipid based Nanocarriers for Oral Delivery of Cancer Chemotherapeutics: An Insight in the Intestinal Lymphatic Transport
Drug Delivery Letters Learning from Metabolic Networks: Current Trends and Future Directions for Precision Medicine
Current Medicinal Chemistry Restless Legs Syndrome/Willis-Ekbom Disease and Periodic Limb Movements: A Comprehensive Review of Epidemiology, Pathophysiology, Diagnosis and Treatment Considerations
Current Rheumatology Reviews PET Imaging to Monitor Cancer Therapy
Current Pharmaceutical Biotechnology Meet the Editorial Board:
Current Drug Targets Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery The Biological Role of mTOR in the Pathogenesis of Solid Tumors: An Overview
Current Enzyme Inhibition MicroRNA-7 Regulates Insulin Signaling Pathway by Targeting IRS1, IRS2, and RAF1 Genes in Gestational Diabetes Mellitus
MicroRNA Cigarette Smoking in Methadone Maintained Patients: An Up-to-Date Review
Current Drug Abuse Reviews MicroRNAs and Cancer Therapy – From Bystanders to Major Players
Current Medicinal Chemistry Recent Advances in Endocrine Metabolic Immune Disorders Drug Targeting: An Editorial Overview
Endocrine, Metabolic & Immune Disorders - Drug Targets Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery
Current Pharmaceutical Design